Translational Informatics for Parkinson’s Disease: from Big Biomedical Data to Small Actionable Alterations

Parkinson's disease (PD) is a common neurological disease in elderly people, and its morbidity and mortality are increasing with the advent of global ageing. The traditional paradigm of moving from small data to big data in biomedical research is shifting toward big data-based identification of small actionable alterations. To highlight the use of big data for precision PD medicine, we review PD big data and informatics for the translation of basic PD research to clinical applications. We emphasize some key findings in clinically actionable changes, such as susceptibility genetic variations for PD risk population screening, biomarkers for the diagnosis and stratification of PD patients, risk factors for PD, and lifestyles for the prevention of PD. The challenges associated with the collection, storage, and modelling of diverse big data for PD precision medicine and healthcare are also summarized. Future perspectives on systems modelling and intelligent medicine for PD monitoring, diagnosis, treatment, and healthcare are discussed in the end.

[1]  J. Perlmutter,et al.  Predictors of survival in patients with Parkinson disease. , 2012, Archives of neurology.

[2]  Agostino Baruzzi,et al.  Skin nerve &agr;-synuclein deposits: A biomarker for idiopathic Parkinson disease , 2014, Neurology.

[3]  John P A Ioannidis,et al.  Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. , 2016, Parkinsonism & related disorders.

[4]  Lucila Ohno-Machado.  Sharing data for the public good and protecting individual privacy: informatics solutions to combine different goals , 2013, J. Am. Medical Informatics Assoc..

[5]  Penny A. MacDonald,et al.  Relationship between Freezing of Gait and Anxiety in Parkinson's Disease Patients: A Systemic Literature Review , 2019, Parkinson's disease.

[6]  Humam Kadara,et al.  Smoking and Lung Cancer: A Geo-Regional Perspective , 2017, Front. Oncol..

[7]  Junfeng Xia,et al.  Biomedical Data Integration, Modeling, and Simulation in the Era of Big Data and Translational Medicine , 2014, BioMed research international.

[8]  C. Ballard,et al.  CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias , 2010, Neurology.

[9]  Bairong Shen,et al.  Knowledge-Guided Bioinformatics Model for Identifying Autism Spectrum Disorder Diagnostic MicroRNA Biomarkers , 2016, Scientific Reports.

[10]  Michel Goedert,et al.  Familial Parkinson's disease: The awakening of α-synuclein , 1997, Nature.

[11]  Filippo Baldacci,et al.  Reliability of administrative data for the identification of Parkinson’s disease cohorts , 2015, Neurological Sciences.

[12]  Lynn Rochester,et al.  Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease , 2017, Neurology.

[13]  Norbert Schuff,et al.  Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort , 2018, Movement disorders : official journal of the Movement Disorder Society.

[14]  Jiajia Chen,et al.  Deciphering oncogenic drivers: from single genes to integrated pathways , 2015, Briefings Bioinform..

[15]  Tomoyuki Miyamoto,et al.  Circadian Variation of Core Body Temperature in Parkinson Disease Patients with Depression: A Potential Biological Marker for Depression in Parkinson Disease , 2008, Neuropsychobiology.

[16]  Thomas Gasser,et al.  Personalized Medicine Approaches in Parkinson's Disease: The Genetic Perspective. , 2016, Journal of Parkinson's disease.

[17]  Bairong Shen,et al.  Physiological Informatics: Collection and Analyses of Data from Wearable Sensors and Smartphone for Healthcare. , 2017, Advances in experimental medicine and biology.

[18]  A. Bakker,et al.  Clinical Markers of Anxiety Subtypes in Parkinson Disease , 2018, Journal of geriatric psychiatry and neurology.

[19]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[20]  Bairong Shen,et al.  Translational Biomedical Informatics in the Cloud: Present and Future , 2013, BioMed research international.

[21]  Ekaterina Nosova,et al.  α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease , 2016, Annals of neurology.

[22]  Rob Knight,et al.  Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease , 2016, Cell.

[23]  Mahesh B. Shenai,et al.  The Relationship of Electrophysiologic Subthalamic Nucleus Length as a Predictor of Outcomes in Deep Brain Stimulation for Parkinson Disease , 2017, Stereotactic and Functional Neurosurgery.

[24]  L. Parr-Brownlie,et al.  A neuroscience perspective of the gut theory of Parkinson's disease , 2019, The European journal of neuroscience.

[25]  Jiajia Chen,et al.  Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer , 2013, BMC Systems Biology.

[26]  Ying Wang,et al.  Identifying novel prostate cancer associated pathways based on integrative microarray data analysis , 2011, Comput. Biol. Chem..

[27]  Chao Xu,et al.  NDDVD: an integrated and manually curated Neurodegenerative Diseases Variation Database , 2018, Database J. Biol. Databases Curation.

[28]  Valeria Dibilio,et al.  Single Photon Emission Computed Tomography Striatal Asymmetry Index May Predict Dopaminergic Responsiveness in Parkinson Disease , 2011, Clinical neuropharmacology.

[29]  Jiajia Chen,et al.  Informatics for Precision Medicine and Healthcare. , 2017, Advances in experimental medicine and biology.

[30]  Hardy J Rideout,et al.  Neuronal death signaling pathways triggered by mutant LRRK2. , 2017, Biochemical Society transactions.

[31]  Marcelo Machado Ferro,et al.  Depression in Parkinson's Disease: The Contribution from Animal Studies , 2017, Parkinson's disease.

[32]  K. Chaudhuri,et al.  Personalized medicine in Parkinson's disease: Time to be precise , 2017, Movement disorders : official journal of the Movement Disorder Society.

[33]  Paolo Barone,et al.  Personality in Parkinson's disease: Clinical, behavioural and cognitive correlates , 2017, Journal of the Neurological Sciences.

[34]  Jiaquan Xu,et al.  Deaths: preliminary data for 2011. , 2012 .

[35]  A. Singleton,et al.  Genetic risk factors in Parkinson’s disease , 2018, Cell and Tissue Research.

[36]  M Goedert.  Familial Parkinson's disease. The awakening of alpha-synuclein. , 1997, Nature.

[37]  Pierre R. Burkhard,et al.  What Is the Best Electrophysiologic Marker of the Outcome of Subthalamic Nucleus Stimulation in Parkinson Disease? , 2018, World neurosurgery.

[38]  Donna Spiegelman,et al.  Prenatal and early life factors and risk of Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[39]  Xiangtian Yu,et al.  Individual-specific edge-network analysis for disease prediction , 2017, Nucleic acids research.

[40]  E. Mayer,et al.  Gut/brain axis and the microbiota. , 2015, The Journal of clinical investigation.

[41]  A. Schapira,et al.  LRRK2 as a therapeutic target in Parkinson’s disease , 2011, European journal of neurology.

[42]  Seunggyun Ha,et al.  Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging , 2017, NeuroImage: Clinical.

[43]  Jihoon Kim,et al.  Mechanisms to protect the privacy of families when using the transmission disequilibrium test in genome-wide association studies , 2017, Bioinform..

[44]  Heather Wood.  Parkinson disease: Plasma α-synuclein — a potential marker of cognitive impairment in Parkinson disease , 2017, Nature Reviews Neurology.

[45]  R. Barker,et al.  Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease. , 2014, Parkinsonism & related disorders.

[46]  T. Dawson,et al.  Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. , 2012, Trends in pharmacological sciences.

[47]  H. Rhinn,et al.  Parkinson's disease: Guilt by genetic association , 2016, Nature.

[48]  M. Toft,et al.  Parkinson's disease: the genetics of a heterogeneous disorder , 2006, European journal of neurology.

[49]  G. Defazio,et al.  Smoking in Patients with Parkinson's Disease: preliminary striatal DaT‐SPECT findings , 2016, Acta neurologica Scandinavica.

[50]  Beate Ritz,et al.  α-Synuclein Genetic Variants Predict Faster Motor Symptom Progression in Idiopathic Parkinson Disease , 2012, PloS one.

[51]  Nicolaas I Bohnen,et al.  Neuroimaging and clinical predictors of fatigue in Parkinson disease. , 2016, Parkinsonism & related disorders.

[52]  Bartha M Knoppers,et al.  Questioning the limits of genomic privacy. , 2012, American journal of human genetics.

[53]  Jong Bhak,et al.  PDbase: a database of Parkinson's Disease-related genes and genetic variation using substantia nigra ESTs , 2009, BMC Genomics.

[54]  E. Basar,et al.  Cognitive Impairment in Parkinson’s Disease Is Reflected with Gradual Decrease of EEG Delta Responses during Auditory Discrimination , 2018, Front. Psychol..

[55]  M. Kuijf,et al.  Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review , 2018, Movement disorders : official journal of the Movement Disorder Society.

[56]  David Gomez-Cabrero,et al.  ParkDB: a Parkinson’s disease gene expression database , 2011, Database J. Biol. Databases Curation.

[57]  Nita A. Farahany,et al.  Redefining Genomic Privacy: Trust and Empowerment , 2014, bioRxiv.

[58]  Michael Backes,et al.  Simulating the Large-Scale Erosion of Genomic Privacy Over Time , 2018, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[59]  John C. Earls,et al.  A wellness study of 108 individuals using personal, dense, dynamic data clouds , 2017, Nature Biotechnology.

[60]  Jiajia Chen,et al.  Interactions Between Genetics, Lifestyle, and Environmental Factors for Healthcare. , 2017, Advances in experimental medicine and biology.

[61]  M. Nalls,et al.  Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease , 2017, PloS one.

[62]  Bruce R Korf,et al.  Genomic privacy in the information age. , 2013, Clinical chemistry.

[63]  Shen-Yang Lim,et al.  Integrating Patient Concerns into Parkinson’s Disease Management , 2017, Current Neurology and Neuroscience Reports.

[64]  Nobuyuki Ishii,et al.  Clinical features and electrocardiogram parameters in Parkinson’s disease , 2017, Neurology International.

[65]  Bairong Shen,et al.  Computer-aided biomarker discovery for precision medicine: data resources, models and applications , 2019, Briefings Bioinform..

[66]  Luca Presotto,et al.  Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease , 2018, Neurology.

[67]  Sur Sharma,et al.  Skin nerve α-synuclein deposits: A biomarker for idiopathic Parkinson disease , 2014, Neurology.

[68]  Reinhold Scherer,et al.  Grip Force Modulation Characteristics as a Marker for Clinical Disease Progression in Individuals With Parkinson Disease: Case-Control Study , 2014, Physical Therapy.

[69]  L J Currie,et al.  Maternal age is not a risk factor for Parkinson's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[70]  C. Adler,et al.  Quantitative EEG as a predictive biomarker for Parkinson disease dementia , 2011, Neurology.

[71]  Marc Cruts,et al.  Locus-Specific Mutation Databases for Neurodegenerative Brain Diseases , 2012, Human mutation.

[72]  Leslie M. Shaw,et al.  Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls , 2017, Neurology.

[73]  Bairong Shen,et al.  Protein interaction network constructing based on text mining and reinforcement learning with application to prostate cancer. , 2015, IET systems biology.

[74]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[75]  Bairong Shen,et al.  New genes drive the evolution of gene interaction networks in the human and mouse genomes , 2015, Genome Biology.

[76]  Meiyi Li,et al.  Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma , 2018, Nature Communications.

[77]  Daniel Weintraub,et al.  CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease , 2015, Journal of Molecular Neuroscience.

[78]  Jihoon Kim,et al.  PRINCESS: Privacy‐protecting Rare disease International Network Collaboration via Encryption through Software guard extensionS , 2017, Bioinform..

[79]  Henrik Zetterberg,et al.  CSF Aβ42 predicts early-onset dementia in Parkinson disease , 2014, Neurology.

[80]  H. Braak,et al.  A timeline for Parkinson's disease. , 2010, Parkinsonism & related disorders.